Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia

被引：8
|
作者：
Allen, Steven L. [1 ]
Kolitz, Jonathan E. [2 ]
Lundberg, Ante S. [3 ]
Bennett, John M. [4 ]
Capizzi, Robert L. [3 ]
Budman, Daniel R. [2 ]
机构：
[1] N Shore Univ Hosp, Albert Einstein Coll Med, Monter Canc Ctr, Lake Success, NY 11042 USA
[2] New York Univ, N Shore Univ Hosp, Monter Canc Ctr, Sch Med, Lake Success, NY USA
[3] Antisoma, Cambridge, MA USA
[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
LEUKEMIA RESEARCH | 2010年 / 34卷 / 04期
关键词：
AML; Phase I; P-glycoprotein; Pgp; Multidrug resistance; SOUTHWEST-ONCOLOGY-GROUP; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; MYELODYSPLASTIC-SYNDROME; POSTREMISSION THERAPY; ANTITUMOR-ACTIVITY; ELDERLY-PATIENTS; GROUP-B; CANCER; INDUCTION;
D O I：
10.1016/j.leukres.2009.07.038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Amonafide-L-malate ( amonafide) is a unique DNA intercalator that maintains activity in the presence of MDR mechanisms, a frequent cause of treatment-failure in secondary AML. 43 patients with relapsed/refractory or secondary AML or CML blast crisis were enrolled into two phase I dose-escalation studies investigating amonafide as monotherapy or in combination with cytarabine. 3/17 patients in the monotherapy trial and 10/26 patients in the combination trial achieved a complete remission. Between both trials responses occurred in 9/20 patients with secondary AML. Both trials demonstrated an acceptable safety profile and significant antileukemic activity in patients with poor-risk AML, especially those with secondary AML. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：487 / 491
页数：5
相关论文
共 50 条
  • [21] Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
    Ottmann, Oliver G.
    Mueller-Tidow, Carsten
    Kraemer, Alwin
    Schlenk, Richard F.
    Luebbert, Michael
    Bug, Gesine
    Krug, Utz
    Bochtler, Tilmann
    Voss, Florian
    Taube, Tillmann
    Liu, Dan
    Garin-Chesa, Pilar
    Doehner, Hartmut
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (06) : 1017 - 1020
  • [22] Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics
    Saliba, Antoine N.
    Boswell, H. Scott
    Cripe, Larry D.
    Abu Zaid, Mohammad Issam
    Weisenbach, Jill
    Sayar, Hamid
    BLOOD, 2017, 130
  • [23] The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia
    Knapper, Steven
    HAEMATOLOGICA, 2015, 100 (09) : 1105 - 1107
  • [24] Improved Responses with Azacitidine Compared to Decitabine in Patients with Acute Myeloid Leukemia in Patients ≥70 with Poor-Risk Cytogenetics
    Talati, Chetasi
    Kuykendall, Andrew
    Al-Ali, Najla
    Komrokji, Rami
    Padron, Eric
    Sallman, David
    List, Alan
    Sweet, Kendra
    Extermann, Martine
    Lancet, Jeffrey
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S295 - S295
  • [25] Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia
    Wilhelm, Christian
    Neubauer, Andreas
    Burchert, Andreas
    LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 2031 - 2035
  • [26] Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia
    Stone, Richard M.
    Mazzola, Emanuele
    Neuberg, Donna
    Allen, Steven L.
    Pigneux, Arnaud
    Stuart, Robert K.
    Wetzler, Meir
    Rizzieri, David
    Erba, Harry P.
    Damon, Lloyd
    Jang, Jun-Ho
    Tallman, Martin S.
    Warzocha, Krzysztof
    Masszi, Tamas
    Sekeres, Mikkael A.
    Egyed, Miklos
    Horst, Heinz-August
    Selleslag, Dominik
    Solomon, Scott R.
    Venugopal, Parameswaran
    Lundberg, Ante S.
    Powell, Bayard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (11) : 1252 - +
  • [27] Oral Debio 1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study
    DiPersio, John F.
    Erba, Harry P.
    Larson, Richard A.
    Luger, Selina M.
    Tallman, Martin S.
    Brill, Jeffrey M.
    Vuagniaux, Gregoire
    Rouits, Elisabeth
    Sorensen, J. Mel
    Zanna, Claudio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (07): : 443 - 449
  • [28] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Norbert Vey
    Hagop Kantarjian
    Miloslav Beran
    Susan O'Brien
    Jorge Cortes
    Charles Koller
    Elihu Estey
    Investigational New Drugs, 1999, 17 : 89 - 95
  • [29] Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study
    Vey, N
    Kantarjian, H
    Beran, M
    O'Brien, S
    Cortes, J
    Koller, C
    Estey, E
    INVESTIGATIONAL NEW DRUGS, 1999, 17 (01) : 89 - 95
  • [30] A PHASE I TRIAL OF LENALIDOMIDE IN COMBINATION WITH INTERMEDIATE DOSE CYTARABINE (IDC) IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) PATIENTS
    Vigil, E.
    Griffiths, A.
    Thompson, E.
    Brady, E.
    Dickey, M.
    Ford, A.
    Wang, S.
    Wetzler, M.
    HAEMATOLOGICA, 2012, 97 : 33 - 33
12345